JD HEALTH deepens cooperation with Helion

AASTOCKS
2026.01.15 01:18

JD HEALTH (06618.HK) announced a deepened cooperation with multinational consumer health company Haleon. The two parties will comprehensively build a new ecosystem for health services focused on co-management and co-governance of diseases, promoting innovation from chronic disease management to full-cycle health management models. This year, the cooperation will expand to over 15 disease and health areas, including children's growth and development, respiratory system, mental health, skin and hair management, digestive health, and sexual health.

Haleon was spun off from GlaxoSmithKline (GSK.US) in 2022 and owns consumer health brands such as Panadol, Sensodyne, Voltaren, Flonase, and Centrum. JD HEALTH stated that as the largest, most comprehensive, and fastest-performing pharmaceutical and health retail channel in China, the company has the most extensive coverage of medical health services. Since last year, Haleon has successively launched multiple new products on the JD HEALTH platform, completing the iteration of 8 OTC products

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.